INBX Stock Overview
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.45 |
| 52 Week High | US$39.79 |
| 52 Week Low | US$14.31 |
| Beta | 2.91 |
| 1 Month Change | -1.54% |
| 3 Month Change | 2.04% |
| 1 Year Change | 75.50% |
| 3 Year Change | 69.45% |
| 5 Year Change | n/a |
| Change since IPO | 66.99% |
Recent News & Updates
Recent updates
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23
Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results
May 16What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?
Jan 14Inhibrx's INBRX-109 wins FDA's Fast Track status
Jan 13Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors
Jan 05Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues
Nov 22Inhibrx EPS misses by $0.07
Nov 13Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.6% | -4.2% | -3.7% |
| 1Y | 75.5% | -2.0% | 20.5% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: INBX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INBX has not had significant price volatility in the past 3 months.
Volatility Over Time: INBX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market cap | US$1.63b |
| Earnings (TTM) | -US$241.36m |
| Revenue (TTM) | US$1.80m |
907.0x
P/S Ratio-6.8x
P/E RatioIs INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$1.80m |
| Cost of Revenue | US$191.64m |
| Gross Profit | -US$189.84m |
| Other Expenses | US$51.52m |
| Earnings | -US$241.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.09 |
| Gross Margin | -10,546.67% |
| Net Profit Margin | -13,408.94% |
| Debt/Equity Ratio | 475.8% |
How did INBX perform over the long term?
See historical performance and comparison